Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Beijing, China.
J Clin Pharm Ther. 2020 Oct;45(5):983-990. doi: 10.1111/jcpt.13115. Epub 2020 Jan 27.
Teicoplanin is widely used for the treatment of infections caused by drug-resistant Gram-positive bacteria. Since there is a good correlation between trough levels and clinical outcome, therapeutic drug monitoring (TDM) is recommended to achieve better clinical curative effects. However, TDM of teicoplanin is not routine in China. So, a programme was initiated in 2017, including both HPLC method establishment and interlaboratory quality assessment, for the measurement of teicoplanin.
A main centre and a quality control centre were set up in the study. An HPLC-based method of teicoplanin determination in plasma was developed by the main centre. Analysis was performed using a Waters Symmetry C18 column (250 mm × 4.6 mm, 5 µm). The mobile phase was NaH PO (0.01 mol/L) and acetonitrile (75:25 v/v; pH 3.3), with a flow rate of 1.0 mL/min and a detection wavelength of 215 nm. Piperacillin sodium was selected as an internal standard (IS). Twenty-six additional TDM centres were then recruited to adopt this method. Then, all the centres were asked to take part in a quality control assessment evaluated by the quality control centre.
For all TDM centres, linearity of teicoplanin concentration ranges was between 3.125 and 100 µg/mL. Intraday and interday accuracies ranged from 87.1% to 118.4%. Intraday and interday precision ranged from 0.3% to 13.8%. Therapeutic drug monitoring centres all passed inter-room quality assessment. All samples tested met the acceptance criteria. Then, 542 samples were collected. Patients with sub-optimal (≤10 mg/L) plasma teicoplanin concentrations constituted 42% of the total study population.
For the first time, a simple, rapid and accurate HPLC method for determining teicoplanin levels was successfully applied to therapeutic drug monitoring in clinical practice for twenty-seven TDM centres in China. The results demonstrated excellent interlaboratory agreement for teicoplanin testing and provide support for clinical laboratory quality management and results inter-accreditation.
替考拉宁被广泛用于治疗耐药革兰阳性菌引起的感染。由于谷浓度与临床疗效有良好的相关性,因此推荐进行治疗药物监测(TDM)以达到更好的临床疗效。然而,替考拉宁的 TDM 在我国尚未常规开展。因此,我们于 2017 年启动了一项计划,包括 HPLC 方法的建立和实验室间质量评估,以用于替考拉宁的检测。
本研究设立了一个主中心和一个质控中心。主中心建立了替考拉宁在血浆中的 HPLC 测定方法。分析采用 Waters Symmetry C18 柱(250mm×4.6mm,5μm)。流动相为 NaHPO(0.01mol/L)和乙腈(75:25v/v;pH3.3),流速为 1.0mL/min,检测波长为 215nm。哌拉西林钠被选为内标(IS)。随后招募了另外 26 家 TDM 中心采用该方法。然后,要求所有中心参加由质控中心评估的质量控制评估。
对于所有 TDM 中心,替考拉宁浓度范围的线性在 3.125 至 100μg/mL 之间。日内和日间准确度在 87.1%至 118.4%之间。日内和日间精密度在 0.3%至 13.8%之间。治疗药物监测中心均通过了室内质量评估。所有检测样本均符合验收标准。然后,共收集了 542 个样本。总研究人群中,有 42%的患者(≤10mg/L)的替考拉宁血浆浓度不理想。
这是首次将一种简单、快速和准确的 HPLC 方法成功应用于中国 27 家 TDM 中心的替考拉宁治疗药物监测,以用于临床实践。结果表明,替考拉宁检测具有良好的实验室间一致性,为临床实验室质量管理和结果互认提供了支持。